Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Tegoprazan or RAPA114 with Atorvastatin
NCT04221321Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Jan 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan and RAPA114 in gastroesophageal reflux disease (GERD) (3 arms), sponsored by HK inno.N Corporation. Primary endpoints: Area under the concentration-time curve over the dosing interval (AUCtau) of atorvastatin and Maximum steady-state plasma concentration (Css,max) of atorvastatin. Started Jan 2020; status: completed.
02
Drugs
tegoprazanRAPA114
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04221321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04221321.